Pro-Dex (PDEX) Q1 2025 earnings summary

Executive summary

• Net sales increased 25% year-over-year to $14.9 million for the quarter ended September 30, 2024, driven by strong growth in orthopedic and CMF medical device sales, repair services, and initial shipments of a next-generation surgical handpiece.

• Net income was $2.5 million, reversing a net loss of $615,000 in the prior year quarter, with EPS of $0.76 (basic) and $0.75 (diluted), aided by $433,000 in unrealized gains on investments.

• Gross margin improved to 35% from 31% year-over-year, reflecting a favorable product mix and higher sales volume.

• CEO anticipates production volume shipments of the new handpiece in the second half of fiscal year 2025.

• Backlog reached $56.8 million, with $45.6 million scheduled for delivery in the remainder of fiscal 2025.

Financial highlights

• Operating income rose to $3.0 million from $1.8 million year-over-year, with operating expenses up 14% to $2.1 million, mainly due to higher personnel costs and bonus accruals.

• Cash and cash equivalents increased to $3.1 million from $2.6 million at June 30, 2024; working capital stood at $27.2 million.

• Net cash provided by operating activities was $1.9 million, up from $392,000 in the prior year quarter.

• Total assets grew to $54.3 million as of September 30, 2024, up from $52.5 million at June 30, 2024.

• Shareholders' equity remained stable at $30.9 million.

Outlook and guidance

• Management expects production shipments of the next-generation orthopedic handpiece to ramp up in Q3 and Q4 of fiscal 2025.

• Revenue growth is anticipated to continue, though not necessarily in a linear fashion, as new product launches and customer inventory needs may cause variability.

• Existing cash, receivables, and operating cash flow are expected to meet liquidity needs for at least the next 12 months.